Labcorp Expands Alzheimer’s Diagnostics with FDA-Approved Blood Test Ahead of Q4 Results

Labcorp US5049221055

Labcorp is signaling a stronger push into diagnostics just ahead of its upcoming quarterly report. The company has rolled out the first FDA-cleared blood test designed to help identify Alzheimer’s risk, carving out a clinically meaningful and potentially lucrative niche. The question remains whether this strategic move will meet Street expectations for the fourth quarter.

The newly launched Elecsys pTau-181 assay targets a patient population of roughly 7.2 million individuals in the United States. Reported negative predictive accuracy is nearly 98%, giving clinicians a reliable tool to rule out Alzheimer’s pathology without resorting to invasive procedures such as spinal taps or costly PET imaging. Labcorp will deploy this test through its extensive network of more than 2,200 service centers to facilitate broad access.

In parallel with the product roll‑out, the company has been pursuing organizational consolidation. Labcorp completed the acquisition of portions of Empire City Laboratories, reinforcing its footprint in the New York metropolitan area. On the governance side, Dr. John H. Sampson joined Labcorp’s Board of Directors this week, bringing medical leadership experience from his role at the University of Colorado.

Focus on the Q4 2025 Results

Investors will get a clearer read on the business when Labcorp reports fourth-quarter 2025 results on Tuesday, February 17, before the U.S. market opens. The consensus among market researchers points to an earnings per share (EPS) of $3.95 on revenue of about $3.56 billion. In the prior quarter, the company topped expectations with an EPS of $4.18.

Key data at a glance:

• Next Earnings Date: February 17, 2026 (before market)
• Expected EPS: $3.95
• Revenue Forecast: $3.56 billion
• Quarterly Dividend: $0.72 (Payable March 12)
• Current Innovation: FDA-approved Alzheimer’s blood test
• Last Acquisition: Empire City Laboratories (closed February 9)

Market Environment and Outlook

The stock currently trades with a market capitalization near $22.74 billion and sits around $281 per share. Analysts’ average price target sits near $300. The share register shows a notably high level of institutional ownership, with professional asset managers holding roughly 96% of the outstanding shares.

As Labcorp releases its quarterly results on Tuesday, the focus will be on whether the company hits the revenue target of $3.56 billion and how the costs associated with the latest expansion have influenced operating margin. The Alzheimer’s blood test represents a key strategic initiative, but investors will scrutinize its short-term impact on profitability and cash flow as part of the broader earnings narrative.

@ boerse-global.de | US5049221055 LABCORP